Takeshi Tsutsumi, Shogo Yamazaki, Takuya Matsuda, Takuya Tsujino, Taizo Uchimoto, Takafumi Yanagisawa, Keiichiro Mori, Wataru Fukuokaya, Fumihiko Urabe, Masanobu Saruta, et al. The Prognostic Significance of Radiographic Progression Without PSA Progression in Patients With Metastatic Hormone-Sensitive Prostate Cancer Treated With First-Line ARPI Therapy. The Prostate. 2026
Kazuki Nishimura, Kensuke Hirosuna, Heima Niigawa, Sho Kakumae, Hirofumi Morinaka, Wataru Fukuokaya, Atsuhiko Yoshizawa, Masanobu Saruta, Saizo Fujimoto, Tsuyoshi Morita, et al. Real-world comparison of enzalutamide and apalutamide in metastatic hormone-sensitive prostate cancer: a multi-institutional propensity score-matched analysis. Japanese journal of clinical oncology. 2026
Kosuke Uchida, Hiromitsu Watanabe, Yuto Matsushita, Keita Tamura, Daisuke Motoyama, Teruo Inamoto. Robot-Assisted Radical Cystectomy Using the Hinotori Surgical System in Patients With Previous Prostate Cancer Treatment: A Single-Institution Case Series. International journal of urology : official journal of the Japanese Urological Association. 2026. 33. 3. e70383
Tsuyoshi Morita, Yutaka Yamamoto, Saizo Fujimoto, Mamoru Hashimoto, Takafumi Minami, Wataru Fukuokaya, Fumihiko Urabe, Takafumi Yanagisawa, Akihito Takeuchi, Ryoichi Maenosono, et al. Comparison of prostate-specific antigen kinetics between androgen receptor signaling inhibitor doublet therapy and androgen receptor signaling inhibitor with docetaxel triplet therapy in patients with metastatic castration-sensitive prostate cancer. Urologic oncology. 2026. 44. 3. 110968-110968
Takafumi Yanagisawa, Keiichiro Mori, Tatsushi Kawada, Satoshi Katayama, Takuya Tsujino, Ryoichi Maenosono, Shingo Toyoda, Takuhisa Nukaya, Hirofumi Morinaka, Keita Tamura, et al. A real-world comparison of nivolumab plus cabozantinib and pembrolizumab plus lenvatinib focusing on safety outcomes in metastatic renal cell carcinoma: results from the JK-FOOT consortium. Cancer immunology, immunotherapy : CII. 2026. 75. 3
